KI intolerance study: A phase 2 study to assess the safety and efficacy of TGR-1202 in pts with chronic lymphocytic leukemia (CLL) who are intolerant to prior BTK or PI3K-delta inhibitor therapy.
Year: 2017
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Colleen Dorsey, Dana Paskalis, Danielle M. Brander, Frederick Lansigan, Paul M. Barr, Nicole Lamanna, Bruce D. Cheson, Jeffrey J. Pu, Marshall T. Schreeder, John M. Pagel, Peter Sportelli, Molly J Fanning, Hari P. Miskin, Tracey Zimmer, Kristy Walsh, Stephen J. Schuster, Eline T. Luning-Prak, E. Paul Wileyto, Michael S. Weiss, Anthony R. Mato
Institutions: Abramson Cancer Center, TG Therapeutics, Inc. (United States), Duke University, Duke Medical Center, Dartmouth–Hitchcock Medical Center, University of Rochester Medicine, Columbia University Irving Medical Center, Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, Penn State Cancer Institute, Clearview Cancer Institute, Hospital of the University of Pennsylvania, University of Pennsylvania
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2889851397